Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Lanxia Liu"'
Publikováno v:
Journal of Nanobiotechnology, Vol 21, Iss 1, Pp 1-14 (2023)
Abstract Certain chemotherapeutics can induce tumor cells’ immunogenic cell death (ICD), release tumor antigens, and thereby trigger personalized antitumor immune responses. Co-delivery of adjuvants using nanocarriers could amplify the ICD-induced
Externí odkaz:
https://doaj.org/article/2221e7d00e5a44bda665b92a69b91d6e
Autor:
Bo Deng, Bing Ma, Yingying Ma, Pei Cao, Xigang Leng, Pengyu Huang, Yuanyuan Zhao, Tianjiao Ji, Xueguang Lu, Lanxia Liu
Publikováno v:
Journal of Nanobiotechnology, Vol 20, Iss 1, Pp 1-14 (2022)
Abstract Chemotherapeutics that can trigger immunogenic cell death (ICD) and release tumor-specific antigens are effective on treating a variety of cancers. The codelivery of chemotherapeutics with adjuvants is a promising strategy to achieve synergi
Externí odkaz:
https://doaj.org/article/2c883afa910c405bac4fae936fbb2856
Publikováno v:
Drug Delivery, Vol 24, Iss 1, Pp 143-151 (2017)
Monitoring drug release and therapeutic efficacy is crucial for developing drug delivery systems. Our preliminary study demonstrated that, as compared with pristine multiwalled carbon nanotubes (MWCNTs), transactivator of transcription (TAT)-chitosan
Externí odkaz:
https://doaj.org/article/d092401a1e8747e8b2e351b4e68c481b
Autor:
Peiru Chen, Dali Wang, Yuyan Wang, Lei Zhang, Qiwei Wang, Lanxia Liu, Jiahe Li, Xin Sun, Mengqi Ren, Ruoxuan Wang, Yang Fang, Jean J. Zhao, Ke Zhang
Publikováno v:
Nano Lett
Nucleic acid-based immune adjuvants have been extensively investigated for the design of cancer vaccines. However, nucleic acids often require the assistance of a carrier system to improve cellular uptake. Yet, such systems are prone to carrier-assoc
Publikováno v:
Biomaterials Science. 8:4757-4766
Combined blockades of CTLA-4 and PD-1 can yield better overall complementary clinical outcomes than individual blockades, but the response rates are still relatively low. To investigate the anti-tumor effects of various combined strategies, we design
Autor:
Tianjiao Ji, Pei Cao, Xueguang Lu, Bo Deng, Bing Ma, Lanxia Liu, Yingying Ma, Xigang Leng, Pengyu Huang
Background: Cancer nanovaccine has become a promising approach for cancer immunotherapy. The major challenge of cancer vaccines is limited efficacy caused by lack of desirable tumor specific antigens (TSA). Chemotherapeutics can trigger immunogenic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba418dac5480a198a86924de976b9ea5
https://doi.org/10.21203/rs.3.rs-1074689/v1
https://doi.org/10.21203/rs.3.rs-1074689/v1
Autor:
Bo Deng, Bing Ma, Yingying Ma, Pei Cao, Xigang Leng, Pengyu Huang, Yuanyuan Zhao, Tianjiao Ji, Xueguang Lu, Lanxia Liu
Publikováno v:
Journal of nanobiotechnology. 20(1)
Chemotherapeutics that can trigger immunogenic cell death (ICD) and release tumor-specific antigens are effective on treating a variety of cancers. The codelivery of chemotherapeutics with adjuvants is a promising strategy to achieve synergistic ther
Autor:
Deling Kong, Mengmeng Yan, Xiaoli Wang, Lanxia Liu, Yijia Liu, Hongfan Sun, Xianghui Zhu, Guilei Ma, Chun Wang
Publikováno v:
ACS Applied Materials & Interfaces. 11:1876-1885
Despite the potential efficacy of immune checkpoint blockade for effective treatment of cancer, this therapeutic modality is not generally curative, and only a fraction of patients respond. Combination approaches provide strategies to target multiple
Publikováno v:
Nano letters. 21(9)
Nanovaccines have emerged as promising agents for cancer immunotherapy. However, insufficient antitumor immunity caused by inefficient antigen/adjuvant loading and complicated preparation processes are the major obstacles that limit their clinical ap
Publikováno v:
Biomaterials science. 9(1)
Biomimetic nanoparticles have potential applications in many fields due to their favorable properties. Here, we developed a self-adjuvanting biomimetic anti-tumor nanovaccine, which was self-assembled with an amphiphilic conjugate synthesized with th